IBRXImmunityBio, Inc.
$10.51+285% 1Y
$10.51
$1.9852 weeks$11.55
The financials
ImmunityBio, Inc. by the numbers
ImmunityBio, Inc. (IBRX) reported revenue of $51M in Q2 2026 (quarter ended Jun 30, 2026), up 94% from the same quarter a year earlier. That came with a gross margin of 99% and net loss of $230M. For the full year FY2025, revenue was $113M (+668% year on year) and net income −$351M. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $51M | $26M | +94% |
| Gross profit | $51M | $26M | +94% |
| Operating income | −$62M | −$71M | n/a |
| Net income | −$230M | −$93M | n/a |
| Diluted EPS | −$0.22 | −$0.10 | n/a |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $568.0K (+1356%)
Product And Service Other grew +14100% year on year
Segment Latestquarter on quarteryear on year
- Product And Service Other$568.0K$568.0Kquarter on quarter +1356%year on year +14100%+1356%+14100%
On our screens:Most shorted stocks